173 related articles for article (PubMed ID: 35698045)
1. Postoperative hyperprogression disease of pancreatic ductal adenocarcinoma after curative resection: a retrospective cohort study.
Zou S; Wang X; Chen H; Lin J; Wen C; Zhan Q; Chen H; Lu X; Deng X; Shen B
BMC Cancer; 2022 Jun; 22(1):649. PubMed ID: 35698045
[TBL] [Abstract][Full Text] [Related]
2. Preoperative risk factors for early recurrence in patients with resectable pancreatic ductal adenocarcinoma after curative intent surgical resection.
Kim NH; Kim HJ
Hepatobiliary Pancreat Dis Int; 2018 Oct; 17(5):450-455. PubMed ID: 30237091
[TBL] [Abstract][Full Text] [Related]
3. Proposed preoperative risk factors for early recurrence in patients with resectable pancreatic ductal adenocarcinoma after surgical resection: A multi-center retrospective study.
Matsumoto I; Murakami Y; Shinzeki M; Asari S; Goto T; Tani M; Motoi F; Uemura K; Sho M; Satoi S; Honda G; Yamaue H; Unno M; Akahori T; Kwon AH; Kurata M; Ajiki T; Fukumoto T; Ku Y
Pancreatology; 2015; 15(6):674-80. PubMed ID: 26467797
[TBL] [Abstract][Full Text] [Related]
4. Postoperative serum CEA and CA125 levels are supplementary to perioperative CA19-9 levels in predicting operative outcomes of pancreatic ductal adenocarcinoma.
Xu HX; Liu L; Xiang JF; Wang WQ; Qi ZH; Wu CT; Liu C; Long J; Xu J; Ni QX; Yu XJ
Surgery; 2017 Feb; 161(2):373-384. PubMed ID: 27838102
[TBL] [Abstract][Full Text] [Related]
5. Tumor copy number instability is a significant predictor for late recurrence after radical surgery of pancreatic ductal adenocarcinoma.
Wen C; Deng X; Ren D; Song X; Chen H; Wang J; Jin J; Cheng D; Xu Z; Zhang J; Xie J; Qi W; Gu J; Peng C; Chen D; Chen S; Shen B; Zhan Q
Cancer Med; 2020 Oct; 9(20):7626-7636. PubMed ID: 32862515
[TBL] [Abstract][Full Text] [Related]
6. The predictors and patterns of the early recurrence of pancreatic ductal adenocarcinoma after pancreatectomy: the influence of pre- and post- operative adjuvant therapy.
Suto H; Okano K; Oshima M; Ando Y; Takahashi S; Shibata T; Kamada H; Kobara H; Masaki T; Suzuki Y
BMC Surg; 2019 Dec; 19(1):186. PubMed ID: 31796066
[TBL] [Abstract][Full Text] [Related]
7. [Analysis of factors influencing recurrence and metastasis following curative resection of pancreatic ductal adenocarcinoma].
Xie YB; Zhao P; Wang CF; Shan Y; Zhao DB; Liu Q; Bai XF
Zhonghua Zhong Liu Za Zhi; 2008 Sep; 30(9):686-9. PubMed ID: 19173911
[TBL] [Abstract][Full Text] [Related]
8. A single center experience in resectable pancreatic ductal adenocarcinoma : the limitations of the surgery-first approach. Critical review of the literature and proposals for practice update.
Dumont R; Puleo F; Collignon J; Meurisse N; Chavez M; Seidel L; Gast P; Polus M; Loly C; Delvenne P; Meunier P; Hustinx R; Deroover A; Detry O; Louis E; Martinive P; Van Daele D
Acta Gastroenterol Belg; 2017; 80(4):451-461. PubMed ID: 29560639
[TBL] [Abstract][Full Text] [Related]
9. Patterns, Timing, and Predictors of Recurrence Following Pancreatectomy for Pancreatic Ductal Adenocarcinoma.
Groot VP; Rezaee N; Wu W; Cameron JL; Fishman EK; Hruban RH; Weiss MJ; Zheng L; Wolfgang CL; He J
Ann Surg; 2018 May; 267(5):936-945. PubMed ID: 28338509
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of adjacent organ resection in patients with left-sided pancreatic ductal adenocarcinoma following distal pancreatectomy.
Song KB; Kwon J; Kim YW; Hwang DW; Lee JH; Hong S; Lee JW; Hwang K; Yoo D; Kim SC
J Hepatobiliary Pancreat Sci; 2019 Jun; 26(6):227-234. PubMed ID: 30980486
[TBL] [Abstract][Full Text] [Related]
11. Development of a Biomarker-Based Scoring System Predicting Early Recurrence of Resectable Pancreatic Duct Adenocarcinoma.
Ishido K; Kimura N; Wakiya T; Nagase H; Hara Y; Kanda T; Fujita H; Hakamada K
Ann Surg Oncol; 2022 Feb; 29(2):1281-1293. PubMed ID: 34608555
[TBL] [Abstract][Full Text] [Related]
12. Early and late recurrence patterns of pancreatic ductal adenocarcinoma after pancreaticoduodenectomy: a multicenter study.
Zhang XP; Xu S; Gao YX; Zhao ZM; Zhao GD; Hu MG; Tan XL; Lau WY; Liu R
Int J Surg; 2023 Apr; 109(4):785-793. PubMed ID: 36999776
[TBL] [Abstract][Full Text] [Related]
13. Infiltrating immune cells and gene mutations in pancreatic ductal adenocarcinoma.
Wang WQ; Liu L; Xu HX; Wu CT; Xiang JF; Xu J; Liu C; Long J; Ni QX; Yu XJ
Br J Surg; 2016 Aug; 103(9):1189-99. PubMed ID: 27256393
[TBL] [Abstract][Full Text] [Related]
14. Preoperative evaluation of pancreatic ductal adenocarcinoma with synchronous liver metastasis: Diagnosis and assessment of unresectability.
Shi HJ; Jin C; Fu DL
World J Gastroenterol; 2016 Dec; 22(45):10024-10037. PubMed ID: 28018110
[TBL] [Abstract][Full Text] [Related]
15. CA19-9 on Postoperative Surveillance in Pancreatic Ductal Adenocarcinoma: Predicting Recurrence and Changing Prognosis over Time.
Rieser CJ; Zenati M; Hamad A; Al Abbas AI; Bahary N; Zureikat AH; Zeh HJ; Hogg ME
Ann Surg Oncol; 2018 Nov; 25(12):3483-3491. PubMed ID: 29786131
[TBL] [Abstract][Full Text] [Related]
16. Predictive risk factors for early recurrence in patients with localized pancreatic ductal adenocarcinoma who underwent curative-intent resection after preoperative chemoradiotherapy.
Murata Y; Ogura T; Hayasaki A; Gyoten K; Ito T; Iizawa Y; Fujii T; Tanemura A; Kuriyama N; Kishiwada M; Sakurai H; Mizuno S
PLoS One; 2022; 17(4):e0264573. PubMed ID: 35377885
[TBL] [Abstract][Full Text] [Related]
17. DUPAN-2 as a Risk Factor of Early Recurrence After Curative Pancreatectomy for Patients With Pancreatic Ductal Adenocarcinoma.
Sasaki A; Sakata K; Nakano K; Tsutsumi S; Fujishima H; Futsukaichi T; Terashi T; Ikebe M; Bandoh T; Utsunomiya T
Pancreas; 2023 Feb; 52(2):e110-e114. PubMed ID: 37523601
[TBL] [Abstract][Full Text] [Related]
18. High expression of vascular endothelial growth factor predicts early recurrence and poor prognosis after curative resection for ductal adenocarcinoma of the pancreas.
Niedergethmann M; Hildenbrand R; Wostbrock B; Hartel M; Sturm JW; Richter A; Post S
Pancreas; 2002 Aug; 25(2):122-9. PubMed ID: 12142733
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of preoperative prognostic factors in patients with resectable pancreatic ductal adenocarcinoma.
Izumo W; Higuchi R; Furukawa T; Yazawa T; Uemura S; Shiihara M; Yamamoto M
Scand J Gastroenterol; 2019 Jun; 54(6):780-786. PubMed ID: 31180790
[No Abstract] [Full Text] [Related]
20. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study.
Distler M; Pilarsky E; Kersting S; Grützmann R
Int J Surg; 2013; 11(10):1067-72. PubMed ID: 24161419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
